Novartis AG vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? Novartis AG trades at $152.38 (market cap $295.37B), while Vanguard S&P 500 Growth Index Fund ETF trades at $85.04. The key difference: Novartis AG pays a 3.07% dividend while Vanguard S&P 500 Growth Index Fund ETF pays none, and Vanguard S&P 500 Growth Index Fund ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| NVS | VOOG | |
|---|---|---|
Market Cap | $295.37B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $168.62 | $85.42 |
52-Week Low | $119.31 | $65.32 |
Enterprise Value | $336.69B | — |
Dividend Yield | 3.07% | — |
Trailing returns across standard periods
Latest headlines on both assets
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →